Jun 10 2024

Montana’s Legal Marijuana Market Records $27 Million in Sales for May

In May, Montana continued its robust marijuana market, recording a total of $26.93 million in sales. This figure demonstrates the state’s ongoing strong performance in marijuana sales since legalization.

Recreational marijuana sales played a significant role, contributing $22.86 million, while medical marijuana sales accounted for $4.08 million for the month.

May’s sales mark the 15th consecutive month that marijuana sales have surpassed $25 million in Montana, according to the state’s Cannabis Control Division. The combined total for 2024 has now reached approximately $130 million. In comparison, the total for 2023 was $319 million, generating over $50 million in tax revenue.
Continue reading

Jun 10 2024

Ohio Recreational Marijuana Sales to Begin by the End of June, Possibly Next Week

Licensed recreational marijuana sales will begin for the first time in Ohio history before the end of June, possibly as soon as next week.

On Friday, Ohio’s Division of Cannabis Control began accepting applications from currently operating medical marijuana dispensaries seeking licenses to participate in the state’s recreational marijuana industry. This would allow them to sell marijuana and marijuana products to patients, as well as to anyone 21 and older.

According to State Representative Jamie Callender (R-Concord), Chair of the Joint Committee On Agency Rule Review, which is the rulemaking committee for Ohio’s Department of Cannabis Control, licenses are expected to be approved, and sales are expected to begin, by the end of June, possibly as soon as next week.
Continue reading

Jun 10 2024

DaySavers and the Cannabis Research Coalition Seeking People Interested in Getting Paid to Smoke Joints for Science

DaySavers, “the most compliant and tested pre-rolled cone and rolling paper brand on the market”, announced today their partnership with the Cannabis Research Coalition and The Network of Applied Pharmacognosy (NAP) on a first-of-its-kind study called The Science of Smokeability (SOS), which is looking to pay people to smoke pre-rolls for science.

According to a press release sent today, SOS is a 2+ year series of scientific experiments focusing on analyzing cultivation and processing metrics to evaluate which variables produce the most pleasant and least harmful smoking experience.

Currently, cannabis is cultivated to maximize yield and cannabinoid content. No study to date has ever evaluated how cultivation practices or post-harvest processing impact the smokeability of the final product. The SOS study promises “to contribute significantly to the evolution of the cannabis industry by providing actionable insights that link cultivation and manufacturing practices to consumer experiences.” This research “not only has the potential to improve product quality and consistency, but also promote sustainability, profitability, and a deeper scientific understanding of cannabis as a medicinal and recreational product.”
Continue reading

Jun 10 2024

New York Legislature Sends Governor Bill to Permanently Legalize Marijuana Farmers Markets

Legislation to permanently legalize marijuana farmers markets in New York has been passed by the state’s legislature and sent to Governor Kathy Hochul.

(Photo credit: Ganjapreneur).

The legislation, sponsored by Senator Michelle Hinchey (D) in the Senate and Assemblymember Donna Lupardo (D) in the Assembly, would establish a permanent licensing process for cannabis showcase event permits. A cannabis showcase event “shall mean an event where licensee authorized to conduct retail sales of adult-use cannabis, cannabis products, and cannabis merchandise engages in the sale and showcase of such products away from the licensed premises in demonstrated partnership with a licensed New York state adult-use cannabis cultivator or processor, at showcase events located at farmers’ markets and public markets as defined in section two hundred sixty of the agriculture and markets law or similar such locations, as authorized by the office.

According to its official summary, the measure “provide the NYS Office of Cannabis Management with the authority to draft new regulations that will update and improve upon the regulatory structure of the successful Cannabis Growers Showcase program, which automatically sunset on January 1, 2024.”
Continue reading

Jun 10 2024

Marijuana Rescheduling: Over 15,000 Comments Submitted on DEA’s Proposal

It’s been three weeks since the Drug Enforcement Administration (DEA) filed its plan in the Federal Register to reschedule marijuana. In that time, over 15,000 people have submitted comments.

Since the DEA’s proposal was filed on May 21, launching a 60-day public comment period that ends on July 22, there have been over 15,000 comments submitted.

A little over half of these comments are urging the DEA to go even further than rescheduling marijuana by descheduling it altogether. This would remove marijuana as a controlled substance, effectively decriminalizing it nationwide. Legislation deschedule marijuana currently has 89 sponsors in the US House of Representatives and 18 sponsors in the Senate.
Continue reading

Jun 10 2024

DEA Cancels Hearing on Psychedelics Ban Amid Legal Challenge

The DEA has cancelled a hearing scheduled for today that would have discussed the agency’s proposed plan to prohibit two different psychedelic compounds that scientists are urging them to keep legal.

“As the matter before DEA is currently stayed, no hearing will commence on June 10, 2024,” states a notice by the DEA on the Federal Register, announcing the cancellation of today’s hearing. The agency says the meeting has been postponed indefinitely, and it comes a month after Panacea Plant Sciences (PPS) filed a lawsuit against the DEA in the U.S. District Court for the Western District of Washington seeking to stop the ban.

The proposed rule would place 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) as Schedule I drugs under the Controlled Substances Act (CSA), making them illegal for all purposes including for research and as a medicine. The DEA made a similar attempt to ban these two substances last year, but eventually revoked the effort after a large outcry from from scientists and researchers, many who feel the substances could have medical value.
Continue reading

Jun 09 2024

These 3 States Are Vying to Become the 26th Legal Marijuana State

New Hampshire is set to become the 25th legal marijuana state, marking the halfway point for the entire country. Meanwhile, three other states are competing to become the 26th, raising the possibility that we could end the year with 28 states having legalized recreational marijuana.

Many state legislatures have already adjourned for the year, with a handful having sessions that last throughout the entire year. With that in mind, it seems likely that any state nearing legalization via the legislative process —Hawaii, for example— won’t take action until 2025. However, three states are set to vote this November on initiatives that would legalize recreational marijuana.

Below is a breakdown of these three states:
Continue reading

Jun 09 2024

The 5 Most Popular Sativa-Dominant Marijuana Strains in the US

In the legal marijuana market, there are hundreds of active marijuana strains (there’s 644 in Massachusetts alone), with many being sativa-dominant. Among the numerous options, a few stand out due to their widespread popularity.

Blue Dream (photo credit: Ry Prichard, The Cannabist).

Today, 24 states have legalized recreational marijuana, while 38 states permit medical marijuana use. These states generally feature flourishing legal markets with numerous licensed stores and dispensaries. Some marijuana strains have risen to national prominence, showcasing their lasting appeal.

Based on data from Leafly and multiple state regulatory agencies, here are the top 5 most popular marijuana strains across the U.S.:
Continue reading

Jun 08 2024

Connecticut Board of Physicians Unanimously Approves Female Orgasmic Disorder and Autism as Qualifying Conditions for Medical Marijuana

A board of physicians in Connecticut has voted to add both female orgasmic disorder (FOD) and autism spectrum disorder (ASD) as qualifying medical marijuana conditions.

Connecticut’s Medical Marijuana Program Board of Physicians has unanimously approved two separate petitions to expand the state’s list of qualifying medical marijuana conditions to include FOD and ASD. Although recreational marijuana is legal in Connecticut, medical marijuana patients are allowed to possess twice as much (three ounces compared to1.5), and they can purchase marijuana and marijuana products tax-free.

The board’s recommendations will now be sent to Department of Consumer Protection Commissioner Bryan T. Cafferelli, who has final say on whether or not to officially add the two conditions to the medical marijuana program.
Continue reading

Jun 08 2024

Maine: Over $20 Million in Legal Marijuana Sold in May, Nearly $100 Million for the Year

Maine marijuana sales topped $20 million in May for the first time this year.

According to data from the Maine Office of Cannabis Policy, marijuana sales reached $20,280,736 in May, marking a $1 million increase over the roughly $19 million sold in both March and April. May sales occurred across 381,148 transactions.

The average price per gram of dried marijuana in May increased slightly from last month’s all-time low of $7.18 to $7.41.
Continue reading